PAX2 and breast carcinoma: Considering that luminal tumours are associated with longest disease-free survival [2], and also that increased nuclear localization of PAX2 in tumour cells negatively correlates with tumour recurrence [15], preferential activation of PAX2 in poorly metastatic luminal breast cancer cells suggests that PAX2 activity confers protection against metastasis in these tumours.